Brokers Offer Predictions for CAPR Q1 Earnings

Capricor Therapeutics Inc (NASDAQ:CAPR) – HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Capricor Therapeutics in a research report issued on Thursday, March 20th. HC Wainwright analyst J. Pantginis anticipates that the biotechnology company will post earnings per share of ($0.35) for the quarter. HC Wainwright has a “Buy” rating and a $77.00 price target on the stock. The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.21) per share. HC Wainwright also issued estimates for Capricor Therapeutics’ Q3 2025 earnings at $0.94 EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at $0.15 EPS and FY2026 earnings at ($0.61) EPS.

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $30.00 target price on shares of Capricor Therapeutics in a research note on Thursday. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Capricor Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $34.50.

Capricor Therapeutics Trading Down 10.4 %

Shares of CAPR opened at $12.86 on Monday. The company has a 50-day moving average of $14.06 and a two-hundred day moving average of $14.70. The stock has a market cap of $584.74 million, a P/E ratio of -12.13 and a beta of 4.10. Capricor Therapeutics has a 12-month low of $3.52 and a 12-month high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.15. The business had revenue of $11.13 million during the quarter, compared to the consensus estimate of $9.87 million. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%.

Hedge Funds Weigh In On Capricor Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Summit Investment Advisors Inc. grew its stake in Capricor Therapeutics by 54.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock worth $53,000 after acquiring an additional 1,345 shares during the period. The Manufacturers Life Insurance Company increased its stake in Capricor Therapeutics by 22.4% in the fourth quarter. The Manufacturers Life Insurance Company now owns 12,919 shares of the biotechnology company’s stock valued at $178,000 after purchasing an additional 2,361 shares during the last quarter. Invesco Ltd. lifted its position in Capricor Therapeutics by 20.5% during the fourth quarter. Invesco Ltd. now owns 14,678 shares of the biotechnology company’s stock worth $203,000 after buying an additional 2,500 shares during the period. Russell Investments Group Ltd. boosted its stake in Capricor Therapeutics by 172.8% in the 4th quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company’s stock worth $64,000 after buying an additional 2,947 shares during the last quarter. Finally, Corebridge Financial Inc. grew its holdings in Capricor Therapeutics by 32.2% in the 4th quarter. Corebridge Financial Inc. now owns 18,212 shares of the biotechnology company’s stock valued at $251,000 after buying an additional 4,434 shares during the period. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.